Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction

Brian Godman, Ana Luísa Caires de Souza, Francisco de Assis Acurcio, Augusto Afonso Guerra Júnior

Research output: Contribution to conferenceAbstractpeer-review

62 Downloads (Pure)


The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.
Original languageEnglish
Number of pages1
Publication statusPublished - 2014
EventII International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment” - Brazil, Belo Horizonte, United Kingdom
Duration: 10 Nov 201413 Nov 2014


ConferenceII International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”
CountryUnited Kingdom
CityBelo Horizonte


  • insulin glargine
  • systematic review
  • Brazil
  • law suits

Cite this